New Delhi: India’s pharmaceutical industry continues its rapid climb on the global platform, which is run by strength, innovation and inclusion. In April 2025, according to the India rating on the part of the Fitch Group, quoted by the Press Information Bureau (PIB) on Sunday, Thesector registered a growth of 7.8 percent in April 2025.This growth reflects strong domestic demand and the onset of new products. The country ranks third in the world based on volume and 14th value by volume. It is the largest global supplier of generic drugs, which meets 20 percent of demands worldwide. India also plays an important role in vaccine production, which supplies 55 to 60 percent of UNICEF’s global vaccine needs. In 2023-24, the pharmutical sector did a turnover of Rs 4,17,345 crore, which is more than 10 percent of the annual growth rate in the last five years. The growth of the region has cited the policy initiative launched as a factor for these advances in recent years, from urban manufacturing hubs to rural research facilities for improving cheap medicines, health services and building employment opportunities across the country. Kandras offer generic drugs at prices up to 80% compared to branded people, “saying that these stores provide quality generic drugs at 80 percent lower prices than branded options. The government further claimed that the production linked incentive (PLI) scheme for pharmaceuticals with a outlay of Rs 15,000 crore is supporting 55 projects focused on the production of high-value drugs for conditions like cancer and diabetes. Another PLI scheme worth Rs 6,940 crore targets domestic production of major drug ingredients, including Penicillin G, to reduce dependence on imports. A separate allocation of Rs 3,420 crore under the PLI scheme for medical equipment is running the local construction of advanced equipment such as MRI machines and cardiac implants, further stated in the report.Moving forward about the claim of pharma sector growth, it said, “Then wholesale drug park schemes are promoted with a construction of Rs 3,000 crore in Gujarat, Himachal Pradesh and Andhra Pradesh. In India, in India, costs low and quality for the world.,ALSO READ: India’s export development operated by high -tech and value added sectors led by electronics and engineering in FY25. India’s drug products play an important role in the International Health Service. The country supplies 99 percent of the World Health Organization’s DPT (diphtheria, hupping phlegm and tetanus), 52 percent for BCG vaccine used against tuberculosis and 45 percent for measles vaccine. Foreign investors have also shown strong belief in the Indian pharmaceutical sector. In 2023-24, foreign direct investment in the region reached Rs 12,822 crore. Country allows 100 percent foreign investment in medical equipment and new drug projects, making it an attractive destination for international enterprises.
